Zacks Investment Research downgraded shares of BTG (OTCMKTS:BTGGF) from a hold rating to a sell rating in a report released on Tuesday morning.

According to Zacks, “BTG plc is a healthcare company. Its operating segment consists of Interventional Medicine and Specialty Pharmaceuticals. Interventional Medicine offers treatment of cancer, severe emphysema, severe blood clots and varicoseveins. Specialty Pharmaceuticals helps patients overexposed to certain medications or toxins. BTG plc is headquartered in London, the United Kingdom. “

BTG (BTGGF) opened at $9.91 on Tuesday. BTG has a 1 year low of $6.74 and a 1 year high of $10.04.

TRADEMARK VIOLATION NOTICE: This news story was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this news story on another domain, it was stolen and republished in violation of US & international trademark and copyright laws. The correct version of this news story can be accessed at https://www.thecerbatgem.com/2017/12/22/zacks-investment-research-lowers-btg-btggf-to-sell.html.

Get a free copy of the Zacks research report on BTG (BTGGF)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Stock Ratings for BTG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BTG and related stocks with our FREE daily email newsletter.